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Resveratrol improves motor 
function in patients with muscular 
dystrophies: an open‑label, 
single‑arm, phase IIa study
Kentaro Kawamura1, Shinobu Fukumura1, Koki Nikaido1, Nobutada Tachi2, Naoki Kozuka3, 
Tsugumi Seino3, Kingya Hatakeyama1, Mitsuru Mori2, Yoichi M. Ito4, Akiyoshi Takami5, 
Shiro Hinotsu6, Atsushi Kuno7, Yukihiko Kawasaki1, Yoshiyuki Horio7* & Hiroyuki Tsutsumi1*
Muscular dystrophies (MDs) are inherited disorders characterized by progressive muscle weakness. 
Previously, we have shown that resveratrol (3,5,4′‑trihydroxy‑trans‑stilbene), an antioxidant and an 
activator of the protein deacetylase SIRT1, decreases muscular and cardiac oxidative damage and 
improves pathophysiological conditions in animal MD models. To determine whether resveratrol 
provides therapeutic benefits to patients with MDs, an open‑label, single‑arm, phase IIa trial of 
resveratrol was conducted in 11 patients with Duchenne, Becker or Fukuyama MD. The daily dose 
of resveratrol was 500 mg/day, which was increased every 8 weeks to 1000 and then 1500 mg/
day. Primary outcomes were motor function, evaluated by a motor function measure (MFM) scale, 
muscular strength, monitored with quantitative muscle testing (QMT), and serum creatine kinase 
(CK) levels. Adverse effects and tolerability were evaluated as secondary outcomes. Despite the 
advanced medical conditions of the patients, the mean MFM scores increased significantly from 
34.6 to 38.4 after 24 weeks of medication. A twofold increase was found in the mean QMT scores of 
scapula elevation and shoulder abduction. Mean CK levels decreased considerably by 34%. Diarrhoea 
and abdominal pain was noted in six and three patients, respectively. Resveratrol may provide some 
benefit to MD patients.
Muscular dystrophies (MDs) are inherited myopathic disorders characterized by progressive muscle weakness 
and  disability1. Mutations in a wide range of proteins, including the dystrophin-associated glycoprotein complex, 
which connects the myofibre cytoskeleton to the extracellular matrix, have been implicated in  MDs1. Complete 
loss of the function of dystrophin causes Duchenne muscular dystrophy (DMD), the most common and lethal 
X-linked myopathy, whereas a partial loss of the function results in Becker muscular dystrophy (BMD), which 
has a milder  phenotype1. Mutations in the FKTN gene cause Fukuyama congenital muscular dystrophy (FCMD), 
a fatal and the second most prevalent form in  Japan2. Although novel therapeutic strategies based on stop codon 
readthrough or exon skipping have been  developed3,4, the conventional and reliable medicine for DMD is glu-
cocorticoids, which improve motor function and the quality of life. Glucocorticoids delay the median age of 
loss of mobility in DMD patients by 2.1–4.4 years5, but the medical condition of patients steadily deteriorates 
under medication. In addition, glucocorticoids have other adverse effects such as cushingoid features, weight 
gain, behavioural changes and growth  delay5.
SIRT1, an  NAD+-dependent protein deacetylase, is a mammalian homologue of Sir2 that prolongs lifespan 
when overexpressed in yeast, Caenorhabditis elegans, and Drosophila melanogaster6. SIRT1 deacetylates histones, 
various transcription factors and cytoplasmic proteins and plays critical roles in cell survival by reducing reactive 
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oxygen species (ROS), inhibiting inflammation, and promoting mitochondrial function and  autophagy6,7. SIRT1 
overexpression in the skeletal muscles of mdx mice, an animal model of DMD, decreases serum creatine kinase 
(CK) levels, tissue fibrosis, and myofibril damage and increases their ability to run long distances compared 
with control mdx  mice8.
Resveratrol (3,5,4′-trihydroxy-trans-stilbene), a natural polyphenol found in grapes and red wine, has been 
shown to allosterically activate  SIRT16,7. δ-Sarcoglycan is a component of the dystrophin glycoprotein complex, 
the defect of which leads to severe cardiomyopathy in hamsters. We found that SIRT1 induces antioxidative 
superoxide dismutase 2 (SOD2), and oral administration of resveratrol to δ-sarcoglycan-deficient TO-2 hamsters 
increases cardiac SOD2 levels, attenuates the deterioration of cardiac function and hypertrophy, and signifi-
cantly extends the  lifespan9. Resveratrol administration also improves the pathophysiological manifestations 
of dystrophin-deficient mdx mice. Resveratrol decreases oxidative stress levels in muscles, reduces cardiac and 
muscular fibrosis, increases the expression levels of myosin heavy chains and troponins, and inhibits cardiac 
 hypertrophy10–12. Moreover, long-term administration of resveratrol improves cardiac and muscular function 
with a decrease in serum CK levels to one-third of those in untreated mdx  mice11,12. Thus, resveratrol could be 
a useful medicine for treating MD patients. However, to date, there have been no clinical studies investigating 
this possibility. Because clinical studies show the relatively low toxicity of  resveratrol13, we planned a pilot phase 
IIa study in MD patients to investigate its biological activity.
In the present study, we administered resveratrol to patients with DMD, BMD, or FCMD for 24 weeks. Since 
the diseases had progressed considerably in these patients, motor function, muscular strength, and CK levels 
were evaluated as primary outcomes. Adverse effects and tolerability were also evaluated as secondary outcomes.
Results
Patients and protocol. The mean ages of eleven DMD, BMD, and FCMD patients were 21.0 ± 9.7 years 
(range, 12–39 years), 33.5 ± 8.3 years (range, 23–46 years), and 14.5 ± 2.5 years (range, 12–17 years), respectively, 
and the mean age of all participants was 24.4 ± 11.1 years (range, 12–46 years) (Table 1). One FCMD patient was 
female, and the remaining ten participants were male. One DMD patient and three patients with BMD were 
ambulatory. The other seven patients were unable to walk and needed a wheelchair; therefore, they were assigned 
a grade of 9 on the Vignos  scale14. Resveratrol was orally administered daily to all participants at an initial dose 
of 500 mg/day for 8 weeks (Fig. 1). The dose was then increased every 8 weeks to 1000 and finally to 1500 mg/
day, similar to dosages of resveratrol administered to healthy subjects and patients with cancer or metabolic 
 diseases13. All patients were assessed for motor function, muscle strength, and blood examinations. Mean scores 
of muscle function measure (MFM), quantitative muscle testing (QMT), and serum CK levels of participants 
before resveratrol medication are shown in Table 2.
Motor function. The MFM scale is a sensitive and reliable method for evaluating motor function in neu-
romuscular diseases, including muscular  dystrophy15. Patients’ motor functions were evaluated by the MFM 
scale scores on 32 items in three dimensions. The mean MFM total score of all participants before resveratrol 
administration was 34.6 ± 29.3 (range, 2–85). MFM scores after 16 and 24 weeks of medication were 38.5 ± 31.7 
(range, 2–90) (p = 0.012) and 38.4 ± 31.3 (range, 2–90) (p = 0.017), respectively (Fig. 2a). Thus, long-term admin-
istration of resveratrol significantly increased MFM scores by 10%. Sub-score analyses of D1, D2, and D3 showed 
increasing tendencies, but these did not meet the threshold of statistical significance (Fig. 2b–d), suggesting that 
resveratrol does not improve muscle function specifically but instead affects the whole body. The Brooke and 
Vignos scale grades did not change during this study.
Table 1.  Participants characteristics.
Type Age, years Sex Weight (kg) Genetic testing
Other diagnostic 
basis Vignos scale Brooke scale
1
Duchenne
12 Male 35.9 Deletion of exon 18 Grade 4 Grade 2
2 14 Male 27.5 Deletion of exons 44–47 Family history Grade 9 Grade 4
3 17 Male 45.8 Deletion of exon 11 Grade 9 Grade 6
4 23 Male 47.7 Not available Biopsy Grade 9 Grade 6
5 39 Male 49.8 Not available Family history Grade 9 Grade 6
6
Becker
23 Male 64.0 Deletion of exons 45–48 Grade 2 Grade 1
7 31 Male 71.0 Deletion of exon 3 Grade 9 Grade 6
8 34 Male 64.5 No copy number variation Biopsy Grade 3 Grade 1
9 46 Male 64.0 Deletion of exons 45–48 Biopsy Grade 6 Grade 2
10
Fukuyama
12 Female 26.9 Heterozygous for the founder haplotype Brain MRI Grade 9 Grade 6
11 17 Male 22.6 Homozygous for the founder haplotype Biopsy Grade 9 Grade 6
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Muscle strength. To determine whether muscle strength was affected by resveratrol, we evaluated the mus-
cle strength of each patient. Strength was monitored with quantitative muscle testing (QMT), which is a reliable 
method for evaluating the muscle strength of ambulatory and non-ambulatory MD  patients16–18. Nine differ-
ent QMT scores were measured, but in some patients, certain items could not be scored due to their severe 
muscle weakness or contracture. For example, a 39-year-old patient with DMD could be evaluated only for 
pinch strength. The monitored activities and number of patients assessed were as follows: scapula elevation, 10; 
shoulder abduction, 5; pinch, 11; elbow extension, 5; elbow flexion, 6; hip flexion, 5; knee extension, 6; ankle 
dorsiflexion, 6; and grip, 7 (Table 2, Fig. 3, Supplementary Fig. S1). Scapula elevation was measured in ten par-
ticipants, including three non-ambulatory patients. The administration of resveratrol for 24 weeks increased the 
mean QMT score of scapula elevation from 4.0 ± 2.7 kg-force (kgf) (range, 0.9–8.6 kgf) to 8.3 ± 6.9 kgf (range, 
1.5–24.9 kgf) (p = 0.001) (Fig. 3a), while the mean shoulder abduction strength measured in one DMD patient 
and four patients with BMD increased from 4.4 ± 1.1 kgf (range, 3.0–6.2 kgf) to 9.1 ± 4.3 kgf (range, 3.9–15.1 
kgf) (p = 0.003) (Fig. 3b). QMT scores of elbow extension, elbow flexion, hip flexion, knee extension, and ankle 
dorsiflexion in some patients were markedly improved by resveratrol, but the differences were not significant 
(Supplementary Fig.  S1a–e). Resveratrol had no effect on pinch strength between the thumb and forefinger 
(Fig. 3c) or on grip strength (Supplementary Fig. S1f).
Figure 1.  Protocol for resveratrol administration. Daily doses of resveratrol are shown, and visits along with 
blood and physical examinations are indicated by arrows.
Table 2.  Mean MFM scale and QMT scores of participants before resveratrol administration.
Type of muscular dystrophy
Total (N = 11)Duchenne (N = 5) Becker (N = 4) Fukuyama (N = 2)
Number (%) Range Mean (SD) Number (%) Range Mean (SD) Number (%) Range Mean (SD) Number (%) Range Mean (SD)
MFM scale 5 (100) 2–63 22.2 (21.5) 4 (100) 38–85 64.5 (16.9) 2 (100) 2–10 6 11 (100) 2–85 34.6 (29.3)
QMT pinch 
(N) 5 (100) 0.5–2.4 11.1 (0.7) 4 (100) 0.3–4.9 3.8 (2.1) 2 (100) 0.1–0.5 0.3 11 (100) 0.1–4.9 1.9 (2.0)
QMT grip 










1 (20) – 3.0 (–) 4 (100) 3.5–6.2 4.7 (1.0) 0 (0) – – 5 (45) 3.0–6.2 4.4 (1.1)
QMT elbow 




1 (20) – 2.8 (–) 4 (100) 3.1–9.2 5.7 (2.5) 0 (0) – – 5 (45) 2.8–9.2 5.1 (2.5)
QMT hip 












5 (100) 200–9518 2522 (3518) 4 (100) 431–2807 1601 (1020) 2 (100) 840–1981 1411 11 (100) 200–9518 1985 (2512)
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Figure 2.  Motor function scores following resveratrol administration. (a) Total score, (b) D1 sub-score in 
standing position and transfers, (c) D2 sub-score in axial and proximal motor function, and (d) D3 sub-score in 
distal motor function of each patient are measured with the MFM scale before (Pre) and at 8, 16, and 24 weeks. 
Black lines show mean values. Average values at each visit were compared with those before medication 
and were analysed using ANOVA. Post hoc analysis was performed using Dunnett’s test. P values < 0.05 are 
indicated. NS: not significant.
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Serum CK levels. Serum CK levels in patients were examined once every 4 weeks (Fig. 4a–d). The mean 
CK levels were 1985 ± 2511 IU/L (range, 200–9518 IU/L) before resveratrol administration and 1315 ± 1357 IU/L 
(range, 166–5167 IU/L) after 24 weeks of medication. Thus, a 34% decrease in mean CK levels was achieved by 
resveratrol, but the difference was not statistically significant (p = 0.148) (Fig. 4a).
Serum resveratrol concentrations. Serum resveratrol concentrations in all patients were examined 
every 4 weeks. Levels of serum resveratrol increased in a dose-dependent manner, and the mean resveratrol 
levels at doses of 500, 1000, and 1500 mg/day were 26.4 ± 20.0 ng/mL (range, 2.6–75.9 ng/mL), 36.9 ± 44.7 ng/mL 
(range, < 1.0–215.0 ng/mL), and 92.2 ± 117.7 ng/mL (range, < 1.0–469.0 ng/mL), respectively (Fig. 5a). Serum 
resveratrol concentration and the time interval for blood draw after ingestion in each patient are shown in 
Fig. 5b–d.
Adverse events. Grade 1 diarrhoea was noted in four patients (Table 3). Grade 2 diarrhoea was found in 
two patients administered 1500 mg/day resveratrol. These two patients needed to reduce the dosage from 1500 to 
1000 mg/day. One patient resumed a dose of 1500 mg/day after several days, whereas the other patient (FCMD 
12 y) was maintained at the dose of 1000 mg/day. Grade 1 abdominal pain was observed in three patients. Two 
cases of upper respiratory tract infection and one case of pneumonia were observed during the study. Among 
them, two patients were temporarily hospitalized but left the hospital soon afterwards. During hospitalization, 
they continued to take resveratrol on schedule. Transient alopecia, erythema multiforme, and acneiform rash 
were observed in one patient each. All participants continued to take resveratrol for 24 weeks. Resveratrol did 
not affect blood markers of liver and renal function (Supplementary Table S1).
Discussion
Resveratrol has been used in humans, and previous data show that its toxicity is  limited13. Since resveratrol 
ameliorated pathology and improved the function of MD animal models, we planned this study as a pilot study.
Resveratrol improved motor function and muscle power in the proximal muscles of participants. However, 
the distal muscles of patients were unaffected (Fig. 3c, Supplementary Fig. S1f). One patient with BMD (BMD 
23 y) experienced relief from muscle pain during resveratrol administration, which may have contributed to the 
Figure 3.  Muscle strength following resveratrol administration. (a–c) Time course of muscle strength for (a) 
scapula elevation (N = 10), (b) shoulder abduction (N = 5), and (c) pinch (N = 11) measured by quantitative 
muscle testing (QMT) using a hand-held dynamometer and pinch strength metre before (Pre) and 8, 16, and 
24 weeks after resveratrol administration. The daily dose of each patient is also shown, except that one patient 
with FCMD (FCMD 12 y) received 1000 instead of 1500 mg/day. Black lines show mean values. Average values 
at each visit were compared with those before medication and were analysed using ANOVA. Post hoc analysis 
was performed using Dunnett’s test. P values < 0.05 are indicated. NS: not significant.
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improvement in motor function. The observed increase in patients’ muscle strength following resveratrol treat-
ment was consistent with findings in mdx  mice10,12, in which approximately fivefold increases in slow-fibre-type 
myosin heavy chain and troponin gene transcripts were detected in the biceps femoris  muscles10. Resveratrol 
binds the N-terminal region of the SIRT1 protein, resulting in the allosteric activation of SIRT1  activity7. SIRT1 
deacetylates and activates peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α), which switches 
muscle types from fast to slow  fibres6,7,19. Indeed, transgenic mice overexpressing PGC-1α19 or  SIRT18 show mus-
cle type conversion from fast- to slow-twitch fibres. PGC-1α transgenic mice also show increased resistance to 
muscular  fatigue19. Thus, the beneficial effects of resveratrol on the muscles of MD patients may involve PGC-1α 
activation by SIRT1. In mdx mice, serum CK levels were decreased by the overexpression of SIRT1 in the  muscles8 
and by the long-term administration of  resveratrol12. Recently, we have shown that skeletal muscle-specific 
SIRT1-knockout mice have a fragile muscle cell plasma membrane and that SIRT1 is involved in membrane 
resealing after cell  injury20. In the present study, mean CK levels were decreased by resveratrol, although the 
change was non-significant. We noted that patients with low serum CK levels, i.e., less than 2000 IU/L, showed 
little response to resveratrol treatment, which could be caused by the lack of sufficient muscle mass. Resveratrol 
administration at early disease stages may afford great benefits to MD patients.
Oxidative stress plays a key role in the development of MD  pathology21. Resveratrol decreases ROS levels 
by inducing the expression levels of the antioxidant enzyme superoxide  dismutase9, suppressing superoxide-
generating NADPH  oxidase10, and eliminating damaged mitochondria, a major cellular source of  ROS22, via 
mitochondrial autophagy, known as  mitophagy11,12,23,24. These antioxidative functions of resveratrol are medi-
ated at least in part by the deacetylation and activation of Forkhead box O transcription factors and PGC-1α 
via SIRT1  activation6,7.
Figure 4.  Serum creatine kinase (CK) levels following resveratrol administration. (a) Mean serum CK levels 
of all participants with standard deviation. (b–d) Change in CK activity in each patient with (b) Duchenne, (c) 
Becker, or (d) Fukuyama congenital muscular dystrophy. Black lines show the mean CK levels.
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Cardiomyopathy and subsequent heart failure is a major cause of death in MD patients. Resveratrol suppresses 
cardiac hypertrophy and fibrosis in TO-2  hamsters9 and mdx  mice25, which may be mediated by the deacetyla-
tion and ubiquitin-dependent degradation of transcriptional coactivator p300 via SIRT1  activation25. In the 
present study, we could not detect any improvement in echocardiographic parameters or levels of plasma brain 
natriuretic peptide (BNP), a marker of cardiomyopathy. This may be because all participants showed normal 
BNP levels (< 18.4 pg/ml), and only 2 patients had a reduced ejection fraction of less than 50% (Supplementary 
Table S1). Longer-term administration of resveratrol may be necessary to reveal the cardiac function of resvera-
trol in MD patients.
Resveratrol is rapidly absorbed and yields peak serum concentration at 1 h post  dose13. In the present study, 
the levels of serum resveratrol concentration in MD patients (Fig. 5b–d) were consistent with those in healthy 
Figure 5.  Serum resveratrol concentration at doses of 500, 1000, and 1500 mg/day. (a) Mean serum resveratrol 
levels of all participants with standard deviation (N = 11). (b–d) Serum resveratrol level and time from 
resveratrol ingestion to blood drawing in each patient are shown by a dot. RSV: resveratrol.
Table 3.  Adverse events following resveratrol administration. The numbers of patients are indicated.
Symptom Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Total (%)
Diarrhoea 4 2 6 (54.5)
Abdominal pain 3 3 (27.3)
Upper respiratory infection 1 1 2 (18.2)
Lung infection 1 1 (9.1)
Alopecia 1 1 (9.1)
Erythema multiform 1 1 (9.1)
Rash acneiform 1 1 (9.1)
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 volunteers13. Six (54.5%) and three (27.3%) patients had diarrhoea and abdominal pain, respectively (Table 3). 
These symptoms were transient and tolerable in participants except for the female patient (FCMD 12 y), who 
suffered from severe diarrhoea at the dose of 1500 mg resveratrol. The weight of the patient was only 26.5 kg, 
and she could not continue the dose. Similar to our study, Brown et al. has reported mild to moderate gastro-
intestinal symptoms in healthy volunteers who ingested resveratrol at doses of 2500 and 5000 mg/day26. Two 
patients contracted transient grade 3 upper respiratory and lung infections, and one patient suffered from a 
grade 2 upper respiratory infection. We believe that these events were unrelated to resveratrol since all three 
patients had repeatedly suffered from respiratory infections before the clinical trial and recovered immediately 
while taking resveratrol.
We found that administration of resveratrol to mdx mice with the highest dose (4 g/kg food) is more effective 
in increasing myofibre cross-section area than lower doses of 0.4 g and 0.04 g/kg  food12. However, a moderate 
dose of resveratrol (0.4 g/kg food) also decreases the number of fibres with central nuclei, the number of fine 
fibres, and serum creatine kinase levels. Additionally, it significantly improves motor function in mdx  mice12. 
Resveratrol at 0.4 g/kg food was estimated to be approximately 50 mg/kg body weight/day10. The mean resveratrol 
level at 1000 mg/day was 36.9 ± 44.7 ng/mL (range, < 1.0–215.0 ng/mL) (Fig. 5a), which is consistent with the 
data of Almeida et al.27. The administration of resveratrol to healthy adult subjects at 150 mg six times/day for 13 
doses resulted in a mean plasma concentration of 63.8 ng/mL and a half-life of resveratrol of 2–5  h27. Resveratrol 
at 36.9 ng/mL is equal to 160 nM. Because 160 nM resveratrol was 1/68 of the concentration needed for twofold 
activation of SIRT1 enzymatic activity in vitro28, the activation of SIRT1 by resveratrol in the present study did 
not seem strong. However, other studies show the physiological effects of resveratrol even in small  amounts13,27. 
The administration of resveratrol at 150 mg/day for 30 days significantly decreased plasma glucose, insulin, 
triglycerides and leptin in healthy obese  men29. Using muscular biopsy, Timmers et al. showed that resveratrol 
activates AMPK activity, increases SIRT1 and PGC1α levels, and promotes mitochondrial respiration activity 
in the  muscle29. Based on these findings, we suggest that resveratrol at a dose of 25–50 mg/kg body weight/day 
is sufficient to treat MD patients. The dosing period required to detect an effect of resveratrol seems to be more 
than 4 months for MD patients.
Glucocorticoids have been shown to prolong the survival of patients with  DMD5. In the present study, gluco-
corticoids were treated in only one patient with DMD (DMD 12 y), who showed increased muscle strength and 
motor function without any adverse effects during resveratrol administration. Recently, novel methods to treat 
DMD have been developed. Ataluren is a stop codon readthrough drug for DMD based on nonsense  mutations3, 
and is currently being evaluated in a post-approval safety study in Europe. Eteplirsen is a morpholino antisense 
oligomer that induces the skipping of exon 51 of the dystrophin  gene4, and accelerated approval for this drug was 
obtained from the U.S. Food and Drug Administration in 2016. The use of these kinds of therapies is expected to 
increase, although they have some  limitations30,31. Given its unique mode of action and relatively mild adverse 
effects, resveratrol could combine with glucocorticoids or recent novel medicines such as ataluren and eteplirsen.
A limitation of the present study was that it was not a randomized, double-blind, placebo-controlled trial. We 
could not analyse an untreated group because the number of patients was limited, and three types of MD patients 
with various clinical conditions were recruited. In the case of rare diseases, phase I studies for cancer and phase 
IIa studies for other diseases have been executed without any  control32–36. These trials were planned because 
of problems in recruiting patients, non-uniformity in patients’ disease conditions, the use of an investigational 
drug that has never been administered in humans, no prior information on dose levels, difficulty in preparing 
a control group or difficulty in obtaining the agreement of patients to use a placebo. Usually, if some possibil-
ity concerning effectiveness of the drug is found in a phase IIa study, a phase IIb clinical study is carried out to 
identify the effect and dose of the investigational drug by a randomized and double-blind study.
We repetitively measured the MFM and QMT scores of the participants. Some studies have reported that 
exercises increase the motor function and muscle strength of MD  patients37. For example, the knee flexor maxi-
mum voluntary contraction torque of the limb-girdle in Becker and facioscapulohumeral MD patients increased 
by 13% after a 12-week resistance training  programme38. However, two meta-analyses of exercise interventions 
on muscle strength in MD patients showed no evidence of improvement in muscle strength and in  endurance39. 
Because the average time required for MFM has been reported to be 36 min (range 8–75 min)15, measuring MFM 
and QMT scores once every 8 weeks in the present study was unlikely to improve motor function of the patients. 
Since participants are aware of exercise interventions, the two meta-analyses39 also suggest that placebo effects 
of interventions are minimal on MD patients. Moreover, average muscle strength in DMD patients treated with 
placebo shows similar decline with that of untreated patients during administration for 6  months40. Because 
mean QMT scores of scapula elevation and shoulder abduction increased by twofold 24 weeks after resveratrol 
administration (Fig. 3a,b), it was less likely that the efficacy of resveratrol was a placebo effect.
As mentioned above, our study was a phase IIa study to investigate the possibility of the use of resveratrol in 
MD patients. To determine whether resveratrol could provide benefit for MD patients and be used as a sympto-
matic medication for MDs, a phase IIb study of resveratrol in a multi-centre trial with randomized, double-blind, 
and parallel-group comparison design will be necessary. An evaluation of the long-term effects of resveratrol on 
MD patients in a uniform cohort, such as age-matched young DMD patients, would be benefical.
Methods
Clinical study design. This study was an open-label, single-arm, phase IIa trial. The protocol was approved 
by the Institutional Review Board (IRB) on May 12, 2014 and registered at the University Hospital Medical 
Information Network Clinical Trial Registry (UMIN-CTR Unique ID: UMIN000014836) on August 12, 2014. 
This trial was conducted in accordance with the Declaration of Helsinki and was carried out at Sapporo Medi-
cal University Hospital from June 2014 to September 2015. Patient inclusion criteria were as follows: (1) DMD, 
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BMD, or FCMD diagnosed based on clinical manifestations, family history, pathological findings of muscle 
biopsy, and/or genetic examination; and (2) minimum age of 12 years. Patients with a history of hypersensitivity 
to resveratrol were excluded. The daily dose of resveratrol was 500 mg/day, which was increased every 8 weeks to 
1000 and then to 1500 mg/day. During the 24 weeks of medication, motor activity and blood were examined four 
and seven times, respectively (Fig. 1). Echocardiography and pulmonary function tests were performed prior to 
administration of resveratrol and after 24 weeks of medication (Fig. 1).
Reagents and evaluation methods. Resveratrol (TransMax) was purchased from Biotivia (New York, 
NY, USA). Physical examinations and blood draws were performed as shown in Fig. 1. Motor function and mus-
cle strength were evaluated by well-trained physical therapists prior to the initiation of resveratrol administration 
and at 8, 16, and 24 weeks. Motor function was estimated with the MFM  scale15. The total score was calculated by 
adding the individual scores of 32 items and ranged from 0 to 96. The generic grading at each item is as follows: 
0, does not initiate movement or starting position cannot be maintained; 1, partially completes the exercise; 2, 
completes the exercise with compensations, slowness or obvious clumsiness; and 3, completes the exercise with 
a standard pattern. MFM total score and D1 (standing position and transfers), D2 (axial and proximal motor 
function), and D3 (distal motor function) sub-scores were  analysed15. Muscle strength was evaluated by quan-
titative muscle testing (QMT)16–18. QMT was performed using a hand-held dynamometer (μTas F-1; ANIMA 
Co., Tokyo, Japan), squeeze dynamometer (Smedley Dynamometer TTM-YO II; Tsutsumi Co., Tokyo, Japan), 
and pinch strength metre (SPR-641; SAKAI Medical Co., Tokyo, Japan). Pinch, grip, scapula elevation, shoulder 
abduction, elbow flexion, elbow extension, hip flexion, knee extension, and ankle dorsiflexion were measured. 
Ejection fraction (EF), percent fractional shortening (%FS), and left ventricular end-diastolic diameter (LVDd) 
were measured with echocardiography. Pulmonary function tests and blood were examined at Sapporo Medical 
University Hospital, and resveratrol concentration was measured by liquid chromatography–tandem mass spec-
trometry at Toray Research Center (Tokyo, Japan). Adverse events were classified, and their degree of severity 
was determined according to the Common Terminology Criteria for Adverse Events (CTCAE) v.4.0.
Statistical analysis. As the primary endpoint, the MFM score, QMT score, and CK value were evaluated 
as continuous variables. All data and average values at each visit were plotted. Average values at each visit were 
compared with those before medication and were analysed using ANOVA. Post hoc analysis was performed 
using Dunnett’s test. P < 0.05 was considered statistically significant. For the QMT score, participants in whom 
the baseline value of each item could not be measured were excluded. Statistical analyses were performed using 
SPSS v.22 software (IBM, Armonk, NY, USA).
Ethics declarations. Study approval The protocol was approved by the IRB of Sapporo Medical University 
Hospital on May 12, 2014. The protocol was then slightly modified twice and approved by the IRB on Sep. 18, 
2014 and Jan. 28, 2015. Written informed consent was obtained from all participants or their legal guardians.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
authors on reasonable request.
Received: 21 January 2020; Accepted: 26 October 2020
References
 1. Mercuri, E. & Muntoni, F. Muscular dystrophies. Lancet 381, 845–860 (2013).
 2. Kobayashi, K. et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 394, 
388–392 (1998).
 3. McDonald, C. M. et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): A multicentre, 
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1489–1498 (2017).
 4. Cirak, S. et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phospho-
rodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet 378, 595–605 (2011).
 5. McDonald, C. M. et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne 
muscular dystrophy: A prospective cohort study. Lancet 391, 451–461 (2018).
 6. Chang, H. C. & Guarente, L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol. Metab. 25, 138–145 (2014).
 7. Bonkowski, M. S. & Sinclair, D. A. Slowing ageing by design: The rise of  NAD+ and sirtuin-activating compounds. Nat. Rev. Mol. 
Cell Biol. 17, 679–690 (2016).
 8. Chalkiadaki, A. et al. Muscle-specific SIRT1 gain-of-function increases slow-twitch fibers and ameliorates pathophysiology in a 
mouse model of duchenne muscular dystrophy. PLoS Genet. 10, e1004490. https ://doi.org/10.1371/journ al.pgen.10044 90 (2014).
 9. Tanno, M. et al. Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell 
survival in chronic heart failure. J. Biol. Chem. 285, 8375–8382 (2010).
 10. Hori, Y. S. et al. Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular 
dystrophy. J. Pharmacol. Exp. Ther. 338, 784–794 (2011).
 11. Kuno, A. et al. Resveratrol ameliorates mitophagy disturbance and improves cardiac pathophysiology of Dystrophin-deficient 
mdx mice. Sci. Rep. 8, 15555. https ://doi.org/10.1038/s4159 8-018-33930 -w (2018).
 12. Sebori, R. et al. Resveratrol decreases oxidative stress by restoring mitophagy and improves the pathophysiology of Dystrophin-
deficient mdx mice. Oxid. Med. Cell Longev. 2018, 9179270. https ://doi.org/10.1155/2018/91792 70 (2018).
 13. Cottart, C. H., Nivet-Antoine, V. & Beaudeux, J. L. Review of recent data on the metabolism, biological effects, and toxicity of 
resveratrol in humans. Mol. Nutr. Food Res. 58, 7–21 (2014).




Scientific Reports |        (2020) 10:20585  | https://doi.org/10.1038/s41598-020-77197-6
www.nature.com/scientificreports/
 15. Bérard, C. et al. A motor function measure for neuromuscular diseases. Construction and validation study.. Neuromuscul. Disord. 
15, 463–470 (2005).
 16. Stuberg, W. A. & Metcalf, W. K. Reliability of quantitative muscle testing in healthy children and in children with Duchenne 
muscular dystrophy using a hand-held dynamometer. Phys. Ther. 68, 977–982 (1988).
 17. Connolly, A. M. et al. Outcome reliability in non-ambulatory boys/men with Duchenne muscular dystrophy. Muscle Nerve 51, 
522–532 (2015).
 18. Escolar, D. M. et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 77, 
444–452 (2011).
 19. Lin, J. et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418, 797–801 
(2002).
 20. Fujiwara, D. et al. SIRT1 deficiency interferes with membrane resealing after cell membrane injury. PLoS ONE 14, e0218329. https 
://doi.org/10.1371/journ al.pone.02183 29 (2019).
 21. Blake, D. J., Weir, A., Newey, S. E. & Davies, K. E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. 
Physiol. Rev. 82, 291–329 (2002).
 22. Balaban, R. S., Nemoto, S. & Finkel, T. Mitochondria, oxidants, and aging. Cell 120, 483–495 (2005).
 23. Galluzzi, L. et al. Molecular definitions of autophagy and related processes. EMBO J. 36, 1811–1836 (2017).
 24. Morselli, E. et al. Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J. Cell 
Biol. 192, 615–629 (2011).
 25. Kuno, A. et al. Resveratrol improves cardiomyopathy in dystrophin-deficient mice through SIRT1 protein-mediated modulation 
of p300 protein. J. Biol. Chem. 288, 5963–5972 (2013).
 26. Brown, V. A. et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: Safety, pharmacokinet-
ics, and effect on the insulin-like growth factor axis. Cancer Res. 70, 9003–9011 (2010).
 27. Almeida, L. et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. 
Nutr. Food Res. 53(Suppl 1), S7-15. https ://doi.org/10.1002/mnfr.20080 0177 (2009).
 28. Howitz, K. T. et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191–196 (2003).
 29. Timmers, S. et al. Calorie restriction-like effects of 30 days of Resveratrol  (resVidaTM) supplementation on energy metabolism and 
metabolic profile in obese humans. Cell Metab. 14, 612–622 (2011).
 30. Kesselheim, A. S. & Avorn, J. Approving a problematic muscular dystrophy drug: Implications for FDA policy. JAMA 316, 2357–
2358 (2016).
 31. Wood, C. L. & Cheetham, T. Treatment of Duchenne muscular dystrophy: First small steps. Lancet 390, 1467–1468 (2017).
 32. Riess, J. W. et al. A phase IIa study repositioning desipramine in small cell lung cancer and other high-grade neuroendocrine 
tumors. Cancer Treat. Res. Commun. 23, 100174. https ://doi.org/10.1016/j.ctarc .2020.10017 4 (2020).
 33. Sebastian, M. et al. A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-
small cell lung cancer. Cancer Immunol. Immunother. 68, 799–812 (2019).
 34. Syková, E. et al. Transplantation of mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: Results of phase I/
IIa clinical trial. Cell Transplant. 26, 647–658 (2017).
 35. Tsai, Y. A. et al. Treatment of spinocerebellar ataxia with mesenchymal stem cells: A phase I/IIa clinical study. Cell Transplant. 26, 
503–512 (2017).
 36. Silva, E. C. et al. Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy. Arq. Neurop-
siquiatr. 70, 191–195 (2012).
 37. Umphred, D. A. & Lazoro, R. T. Neurological Rehabilitation, 6th ed (eds. Roller, M. & Burton, G.) 563–565 (Elsevier Health Sci-
ences, 2012).
 38. Bostock, E. L. et al. The effects of resistance exercise training on strength and functional tasks in adults with Limb-Girdle, Becker, 
and Facioscapulohumeral dystrophies. Front Neurol. 10, 1216. https ://doi.org/10.3389/fneur .2019.01216 (2019).
 39. Gianola, S. et al. Efficacy of muscle exercise in patients with muscular dystrophy: A systematic review showing a missed opportunity 
to improve outcomes. PLoS ONE 8, e65414. https ://doi.org/10.1371/journ al.pone.00654 14 (2013).
 40. Griggs, R. C. et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. 
Arch Neurol. 48, 383–388 (1991).
Acknowledgements
This study was supported by grants from the Japanese Ministry of Education, Culture, Sports, Science and 
Technology for Translational Research (Seed A-25); the Japanese Society for the Promotion of Science (JSPS) 
KAKENHI (Grant Numbers, 15K08312 and 18K06965); the Setsuro Fujii Memorial, the Osaka Foundation for 
Promotion of Fundamental Medical Research; and the Hiroshige Kondo Foundation. We thank Shun Shimo-
hama, Tomihiro Imai, Shin Hisahara (Department of Neurology, Sapporo Medical University School of Medicine) 
and Tomoyuki Dobata (Toseikai Healthcare Corporation, Life-Long Care Clinic for Disabled People) for the 
referral of patients.
Author contributions
K.K., A.T., Y.H., and H.T. designed the study. K.K., S.F., K.N., N.T., N.K., T.S., and K.H. executed the study. N.K. 
and T.S. measured muscle strength and motor function. K.K., M.M., Y.M.I., S.H., A.K., Y.K., Y.H., and H.T. 
analysed the data. K.K., Y.H., and H.T. wrote the manuscript. All authors read and approved the final version 
of the manuscript.
Competing interests 
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https ://doi.org/10.1038/s4159 8-020-77197 -6.
Correspondence and requests for materials should be addressed to Y.H. or H.T.
Reprints and permissions information is available at www.nature.com/reprints.




Scientific Reports |        (2020) 10:20585  | https://doi.org/10.1038/s41598-020-77197-6
www.nature.com/scientificreports/
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2020
